Novavax Inc. (NVAX)
NASDAQ: NVAXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NVAX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.23B
- EPS (TTM)
- -$0.52
- Dividend yield
- None
- 52-week range
- 6.36 – 13.39
- Day range
- 7.43 – 7.98
- Volume / Avg
- 4.73M / 6.67M
- Beta
- —
- Shares outstanding
- 165.01M
52-week range
NVAX stock today
Shares of Novavax (NVAX) finished lower on Nov 20 at $7.47, a drop of 3.24% or $0.25 per share, versus the S&P 500's 3.70% decline. Shares are 44.2% below their 52-week high of $13.39, set on Oct 5, 2026 and 17.5% above the 52-week low of $6.36, near the bottom of the past year's range. NVAX is up 11.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 15.5%.
Novavax has posted a net loss over the last twelve months (EPS of -$0.52), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Novavax
Company profileNovavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. John Charles Jacobs M.B.A.
- Headquarters
- Gaithersburg, MD
- Employees
- 749
- Website
- novavax.com
Financial highlights
Full financialsIn fiscal 2025, Novavax generated $1.12 billion in revenue, up 64.7% from fiscal 2024. Net income was $440.3 million, for a net margin of 39.2% versus a median of -55.4% in the prior 5 years. Gross margin was 93.5% (up from 70.3%) and operating margin 40.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.12B | $682.16M | $983.71M | $1.98B | $1.15B |
| Growth | +64.69% | -30.65% | -50.36% | +72.89% | +141.02% |
| Net income | $440.30M | $-187.50M | $-545.06M | $-657.94M | $-1.74B |
| EPS (diluted) | $2.58 | $-1.23 | $-5.41 | $-8.42 | $-23.44 |
Analyst forecast
ForecastConsensus (9 analysts)
buy
Avg. price target
$14.11+88.89%
- Strong buy 0
- Buy 5
- Hold 1
- Sell 1
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.19 vs $-0.37
- Surprise
- +48.65%
NVAX news
All NVAX news- Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine TrialNasdaq
- Novavax to Participate in Jefferies London Healthcare ConferencePR Newswire
- Novavax Consensus Price Target Raised 13.54% to $14.39Nasdaq
- NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs DeclineNasdaqNVAX, SNY, PFE
- Novavax Q3 Earnings Call HighlightsNasdaq
- Novavax outlines $400M 2026 revenue framework while targeting cash runway into 2029Seeking Alpha
- Novavax gains after Q3 beat, guidance hikeSeeking Alpha
- Novavax GAAP EPS of -$0.19 beats by $0.16, revenue of $68.3M beats by $17.88MSeeking Alpha
Novavax peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TSHATaysha Gene Therapies Inc. | 3.72 | -1.33% | $1.21B | vs NVAX |
| VORVor Biopharma Inc. | 19.19 | +3.62% | $1.18B | vs NVAX |
| IMCRImmunocore Holdings plc ADR | 26.41 | -0.83% | $1.36B | vs NVAX |
| MESOMesoblast Limited ADR | 10.89 | -2.59% | $1.41B | vs NVAX |
| INBXInhibrx Biosciences Inc. | 68.97 | -7.21% | $1.02B | vs NVAX |
| WWBWindward Bio Group AG | 24.29 | +1.15% | $1.45B | vs NVAX |
| ALVOAlvotech | 4.12 | -3.96% | $1.47B | vs NVAX |
| RXRXRecursion Pharmaceuticals Inc. Class A | 2.45 | -9.93% | $1.53B | vs NVAX |
Indexes, lists and sector
Novavax stock FAQ
What is Novavax's stock price today?
NVAX last traded at $7.47 as of Nov 20, 4:00 PM EST, down 3.24% on the day. Prices are delayed at least 15 minutes.
Does Novavax pay a dividend?
No. Novavax does not currently pay a regular cash dividend.
Who is Novavax's CEO?
Mr. John Charles Jacobs M.B.A. is the chief executive officer of Novavax Inc., which has about 749 employees.
Has NVAX ever split its stock?
Yes. The most recent NVAX stock split was a 1-for-20 split on May 10, 2019.
What is the NVAX 52-week high?
The 52-week high for NVAX is $13.39 and the 52-week low is $6.36. The stock is currently 44.2% below its high.